Tower Research Capital (TRC)’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Tower Research Capital (TRC)’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,237	Closed	-$11K	–	6447
2023 Q1	$11K	Sell	1,237 -771	-38%	-$10.9K	﹤0.01%	4291
2022 Q4	$24K	Buy	2,008 +1,602	+395%	+$28.3K	﹤0.01%	2979
2022 Q3	$9K	Sell	406 -412	-50%	-$11.1K	﹤0.01%	4719
2022 Q2	$20K	Sell	818 -658	-45%	-$22.4K	﹤0.01%	3817
2022 Q1	$74K	Buy	1,476 +182	+14%	+$8.99K	﹤0.01%	2426
2021 Q4	$91K	Buy	1,294 +263	+26%	+$22.2K	﹤0.01%	2293
2021 Q3	$96K	Sell	1,031 -142	-12%	-$13.5K	﹤0.01%	2436
2021 Q2	$118K	Buy	1,173 +178	+18%	+$17.4K	﹤0.01%	2298
2021 Q1	$93K	Sell	995 -113	-10%	-$11.5K	﹤0.01%	2643
2020 Q4	$91K	Sell	1,108 -5,624	-84%	-$480K	﹤0.01%	2442
2020 Q3	$578K	Buy	6,732 +5,605	+497%	+$653K	0.01%	1524
2020 Q2	$105K	Buy	+1,127	New	+$62.1K	﹤0.01%	2416
2019 Q4	–	Sell	-3,636	Closed	-$52K	–	4541
2019 Q3	$52K	Buy	3,636 +3,407	+1,488%	+$71.3K	﹤0.01%	1775
2019 Q2	$8K	Buy	+229	New	+$12.4K	﹤0.01%	2721
2019 Q1	–	Sell	-66	Closed	-$3K	–	4396
2018 Q4	$3K	Buy	+66	New	+$3.62K	﹤0.01%	3240
2018 Q3	–	Sell	-121	Closed	-$10K	–	4348
2018 Q2	$10K	Buy	121 +4	+3%	+$386	﹤0.01%	2802
2018 Q1	$12K	Buy	117 +97	+485%	+$11.6K	﹤0.01%	2405
2017 Q4	$3K	Sell	20 -105	-84%	-$12.9K	﹤0.01%	3124
2017 Q3	$18K	Buy	125 +102	+443%	+$12.3K	﹤0.01%	2801
2017 Q2	$4K	Buy	23 +16	+229%	+$2.16K	﹤0.01%	2138
2017 Q1	$1K	Sell	7 -13	-65%	-$1.76K	﹤0.01%	2876
2016 Q4	$2K	Sell	20 -17	-46%	-$1.62K	﹤0.01%	3489
2016 Q3	$5K	Buy	37 +24	+185%	+$2.69K	﹤0.01%	2594
2016 Q2	$2K	Sell	13 -60	-82%	-$6.01K	﹤0.01%	3988
2016 Q1	$5K	Buy	+73	New	+$4.83K	﹤0.01%	2753
2015 Q4	–	Sell	-31	Closed	-$2K	–	5163
2015 Q3	$2K	Buy	31 +30	+3,000%	+$2.38K	﹤0.01%	3428
2015 Q2	$0	Sell	1 -22	-96%	-$1.8K	﹤0.01%	5156
2015 Q1	$2K	Sell	23 -6	-21%	-$535	﹤0.01%	3855
2014 Q4	$3K	Buy	29 +25	+625%	+$1.97K	﹤0.01%	3177
2014 Q3	$0	Buy	+4	New	+$442	﹤0.01%	4979
2014 Q1	–	Sell	-4	Closed	-$1K	–	5040
2013 Q4	$1K	Sell	4 -1	-20%	-$165	﹤0.01%	4273
2013 Q3	$1K	Buy	5 +2	+67%	+$390	﹤0.01%	4360
2013 Q2	$0	Buy	+3	New	+$343	﹤0.01%	3991

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tower Research Capital (TRC)'s VBIV Position: Q2 2023 in Review

Tower Research Capital (TRC) sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 1,237 shares — an estimated $11K sold.

Tower Research Capital (TRC) first reported a position in VBIV in Q2 2013 and held it in 33 quarters. The position peaked at $578K in Q3 2020. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

Tower Research Capital (TRC) reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 1,237 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $11K.
Tower Research Capital (TRC) first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2013 and held it in 33 quarters.
Tower Research Capital (TRC)'s VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $578K in Q3 2020.
46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.